Connection

VIKAS KUNDRA to Angiogenesis Inhibitors

This is a "connection" page, showing publications VIKAS KUNDRA has written about Angiogenesis Inhibitors.
Connection Strength

0.418
  1. Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One. 2015; 10(6):e0131095.
    View in: PubMed
    Score: 0.310
  2. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 01; 68(1):206-15.
    View in: PubMed
    Score: 0.046
  3. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007 Oct 01; 67(19):9337-45.
    View in: PubMed
    Score: 0.045
  4. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.